Zentiva, a Czechia-based generics pharmaceutical company, announced on Friday that it has received the ESG Transparency Award 2025, presented by German market research organisation EUPD Group at the ESG Summit 2025.
The award aims to recognise companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting.
EUPD Group said that Zentiva was awarded the Excellence Level of the ESG Transparency Award for its high degree of clarity, accessibility and transparency in sustainability reporting. This distinction places the company among the top organisations in Europe in terms of transparent reporting of its ESG disclosures.
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial